Harvard Management Company’s Vigil Neuroscience VIGL Stock Holding History

Harvard Management Company’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-289,460	Closed	-$1.56M	–	21
2023 Q3	$1.56M	Hold	289,460	–	–	0.18%	16
2023 Q2	$2.72M	Hold	289,460	–	–	0.27%	21
2023 Q1	$2.83M	Hold	289,460	–	–	0.3%	27
2022 Q4	$3.62M	Hold	289,460	–	–	0.45%	26
2022 Q3	$2.63M	Hold	289,460	–	–	0.33%	32
2022 Q2	$747K	Hold	289,460	–	–	0.09%	41
2022 Q1	$2.04M	Buy	+289,460	New	+$3.82M	0.21%	39

Other funds holding VIGL

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Harvard Management Company's VIGL Position: Q4 2023 in Review

Harvard Management Company sold out of Vigil Neuroscience (VIGL) in Q4 2023, closing a stake of 289,460 shares — an estimated $1.56M sold.

Harvard Management Company first reported a position in VIGL in Q1 2022 and held it in 7 quarters. The position peaked at $3.62M in Q4 2022. 46 funds tracked by Wall St. Rank hold VIGL as of Q4 2023.

Harvard Management Company reported no remaining Vigil Neuroscience position as of Q4 2023 after selling out during the quarter.
Harvard Management Company sold 289,460 Vigil Neuroscience shares in Q4 2023, an estimated $1.56M.
Harvard Management Company first reported a position in Vigil Neuroscience in Q1 2022 and held it in 7 quarters.
Harvard Management Company's Vigil Neuroscience position peaked at $3.62M in Q4 2022.
46 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2023.

Based on Harvard Management Company's 13F filing for Q4 2023, filed 9 Feb 2024.